Endothelial dysfunction in MELAS improved by l-arginine supplementation

Neurology. 2006 Jun 13;66(11):1766-9. doi: 10.1212/01.wnl.0000220197.36849.1e.

Abstract

The authors evaluated endothelial function in patients with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke) by flow-mediated vasodilation (FMD) and found a significant decrease vs controls. Two years of supplementation with oral l-arginine, a nitric oxide precursor, significantly improved endothelial function to control levels and was harmonized with the normalized plasma levels of l-arginine in patients. l-Arginine therapy improved endothelial dysfunction and showed promise in treating strokelike episodes in MELAS.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Arginine / administration & dosage*
  • Blood Flow Velocity / drug effects
  • Cerebrovascular Circulation / drug effects*
  • Child
  • Dietary Supplements
  • Endothelium, Vascular / drug effects*
  • Female
  • Humans
  • MELAS Syndrome / diagnosis
  • MELAS Syndrome / drug therapy*
  • Male
  • Middle Aged
  • Stroke / diagnosis
  • Stroke / prevention & control*
  • Vasodilator Agents / administration & dosage

Substances

  • Vasodilator Agents
  • Arginine